Celldex Therapeutics Presents New Clinical Data From Phase 2 Study Of CDX-011 bi13511358 Celldex Therapeutics, Inc. (NASDAQ: CLDX) announced the presentation of promising data on CDX-011 metastatic melanoma at the 46th Annual Meeting of the American Society of Oncology (ASCO) Chicago, Illinois. The Phase 2 study has met primary endpoint and the results support additional studies indication. CDX-011 an antibody-drug conjugate (ADC) Phase 2 ..

Argos Therapeutics Presents Positive Phase 2 Data For Arcelis Dendritic Cell- bi13511358 Argos Therapeutics announced the presentation of positive interim data from a Phase 2 trial that evaluated the activity, safety and immune response of AGS-003 treatment, given combination sunitinib, patients newly diagnosed advanced renal cell carcinoma (RCC). The data were discussed June 7 a poster session at the 46th Annual Meeting of the American Society of ..

VBL Therapeutics to Present Data on VB-201 for Rheumatoid Arthritis at EULAR bi13511358 TEL AVIV, Israel----VBL Therapeutics, a -stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced the upcoming presentation of pre data from the companys lead program, VB-201, at the European League Against Rheumatism Annual European Congress of Rheumatology

Chelsea Therapeutics Announces Update on Antifolate Clinical Program bi13511358 CHARLOTTE, N.C. -- Chelsea Therapeutics International, Ltd. announced that during a teleconference yesterday, the U.S. Food and Drug Administration requested that the company delay the initiation of proposed Phase II study of CH-4051 rheumatoid arthritis and indicated that the agency requesting additional detail from the pre studies previously submitted as part of the ..

Aestus Therapeutics Awarded Multi-Million Dollar Grant for Clinical Studies o bi13511358 NORTH BRUNSWICK, N.J.----Aestus Therapeutics, Inc. announced that has been awarded a $2 million Small Business Innovative Research grant from the National Institutes of Health . The grant, from the NIH's National Institute of Neurological Disorders and Stroke , fund trials of Aestuss novel, first-in-class treatment for chronic neuropathic pain

Clinical Data prices $28M stock offering bi13511358 Data Inc., develops early- and late-stage targeted therapeutics and genetic and pharmacogenomic tests, has taken about $27.8 million after a public stock offering of 1.95 million shares priced at $14.30 per share

Onset Therapeutics Announces Continued Commercial Expansion and Pipeline Prog bi13511358 Onset Therapeutics, a specialty pharmaceutical company focused dermatology, today announced the completion of the Companys latest sales force expansion initiative designed to provide national dermatology coverage to support the success of two recently launched products and the Companys rapidly growing pipeline of products various stages of development. read more..

Positive initial results from Nektar Therapeutics' NKTR-102 Phase 2 study for bi13511358 Nektar Therapeutics today announced positive preliminary initial results from a two-stage Phase 2 study evaluating single-agent NKTR-102 women advanced/metastatic breast cancer patients who have received a prior taxane. The increased use of taxanes breast cancer often renders tumors resistant to these drugs by the time the disease recurs, thereby underscoring the urgent need ..

Onset Therapeutics expands sales force by over 50% 2010 bi13511358 Onset Therapeutics, a specialty pharmaceutical company focused dermatology, today announced the completion of the Company's latest sales force expansion initiative designed to provide national dermatology coverage to support the success of two recently launched products and the Company's rapidly growing pipeline of products various stages of development

Cardium Announces Master Services Agreement With bioRASI for Planned Late-Sta bi13511358 SAN DIEGO, June 10 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) today announced that has entered a Master Services Agreement bioRASI, an international contract research organization, to assist Cardium the conduct of a planned late-stage study and commercialization activities for Cardium's Generx (Ad5FGF-4) drug candidate Russia and affiliated ..

Celldex Therapeutics Presents New Clinical Data From Phase 2 Study Of CDX-011 bi13511358 Celldex Therapeutics, Inc. (NASDAQ: CLDX) announced the presentation of promising data on CDX-011 metastatic melanoma at the 46th Annual Meeting of the American Society of Oncology (ASCO) Chicago, Illinois. The Phase 2 study has met primary endpoint and the results support additional studies indication. CDX-011 an antibody-drug conjugate (ADC) Phase 2 ..

Argos Therapeutics Presents Positive Phase 2 Data For Arcelis Dendritic Cell- bi13511358 Argos Therapeutics announced the presentation of positive interim data from a Phase 2 trial that evaluated the activity, safety and immune response of AGS-003 treatment, given combination sunitinib, patients newly diagnosed advanced renal cell carcinoma (RCC). The data were discussed June 7 a poster session at the 46th Annual Meeting of the American Society of ..

VBL Therapeutics to Present Data on VB-201 for Rheumatoid Arthritis at EULAR bi13511358 TEL AVIV, Israel----VBL Therapeutics, a -stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced the upcoming presentation of pre data from the companys lead program, VB-201, at the European League Against Rheumatism Annual European Congress of Rheumatology

Honda Cbr Accessories - Home